Sand Grove Capital Exhibits Tremendous Foresight With Regard to Celgene This Year.

DateSharesPriceAUM
3/31/19 1,655,500 93.70 $406,391,000
 6/30/19 2,479,495 93.49 $938,823,800
9/30/19 2,578,428 99.30$532,311,000

Nov 21, 2019
(TheStreet) “Celgene shareholders received 1 Bristol-Myers share, $50 in cash and special rights for a further $9 in cash if certain performance milestones under the combined group are met. The January deal valued Celgene at $102.43 each at the time, a 53.7% premium to the previous session’s closing price. The combined group — which will be 69% owned by Bristol-Myers — would have a portfolio with nine drugs that generate more than $1 billion in sales”. Read more

View their holdings

Leave a Reply